Pernicious Anemia: Recognizing and Preventing Irreversible Neurological Damage

Quick Reference for Physicians

Understanding the Severity of Pernicious Anemia

Pernicious anemia causes vitamin B12 deficiency that results in neurological impairment. In 30% of cases, it occurs without anemia or macrocytosis. Neuropsychiatric symptoms frequently represent the initial manifestation and include depression, anxiety, paresthesia, gait disturbances, and cognitive impairment. Despite its name suggesting anemia as the primary feature, neurological complications often precede and may occur independently of hematological abnormalities.

Without adequate treatment, patients will develop:

- Permanent spinal cord damage (subacute combined degeneration)
- Irreversible peripheral neuropathy
- Permanent cognitive impairment and dementia
- Psychiatric symptoms often misdiagnosed as primary mental illness
- Progressive disability and loss of independence

Clinical significance: Neurological damage represents the primary pathological consequence of B12 deficiency and occurs before hematological changes. Early intervention prevents irreversible complications, while delayed treatment results in permanent neurological deficits.

Critical Diagnostic Error: Laboratory Values Do Not Reliably Reflect Tissue B12 Status

No blood test can reliably determine whether nervous system tissue has adequate B12, particularly in malabsorption disorders like pernicious anemia. Normal or elevated laboratory values do not exclude functional B12 deficiency.

Understanding B12 Testing: What Each Test Actually Measures

Serum B12 (Total B12):

- Measures all B12 circulating in blood, including inactive forms
- Poor sensitivity and specificity for detecting deficiency
- Falsely normal in liver disease, kidney disease, malignancies
- Falsely elevated from recent supplementation while patient remains functionally deficient
- Can appear normal or high while patient is functionally deficient at cellular level
- Normal serum B12 documented in patients with severe neurological symptoms

Holotranscobalamin (Active B12):

- Measures B12 bound to transcobalamin—the fraction that can be delivered to cells
- More sensitive than total serum B12 for detecting early deficiency
- Still measures blood transport, not intracellular function
- In malabsorption states including pernicious anemia, transport can appear adequate while cellular utilization fails, especially in nervous system tissue
- Normal holotranscobalamin does not rule out neurological B12 deficiency

Methylmalonic Acid (MMA):

- Rises when B12-dependent enzymes inside cells are not working
- Best available laboratory marker of functional B12 deficiency
- However, MMA can be normal despite cellular deficiency
- More than half of people with low holotranscobalamin (indicating early deficiency) have normal MMA
- Patients with normal MMA, normal homocysteine, AND normal serum B12 have responded clinically to B12 treatment

Homocysteine:

- Elevated in B12 deficiency (less specific than MMA)
- Can be normal despite functional B12 deficiency
- Also elevated in folate deficiency, kidney disease, hypothyroidism

The Hierarchy of B12 Assessment

Laboratory markers (in order of reliability):

1. MMA (best lab marker, but still can miss cellular deficiency)
2. Holotranscobalamin (better than serum B12, but limited in malabsorption)
3. Serum B12 (crude, often misleading)
4. Homocysteine (least specific)

Clinical assessment remains central:

- Symptoms are often more reliable than laboratory values for diagnosis and treatment monitoring
- Normal laboratory values do not rule out clinically significant B12 deficiency
- This is well-documented in clinical literature and professional guidance

Proper Diagnostic Approach

Primary Diagnostic Tests:

Intrinsic Factor Antibodies: Anti-IF antibodies are 40 to 60% sensitive in detecting pernicious anemia, with the rate of positivity rising with disease progression. The specificity of anti-IF antibody testing is almost 100%.

Critical limitation: 40-60% of pernicious anemia patients will have negative antibody tests.

There are two types of IF antibodies: Type 1 (blocking antibodies) that prevent B12 binding to intrinsic factor, and Type 2 (binding antibodies) that prevent the B12-IF complex from attaching to intestinal receptors.

Parietal Cell Antibodies: Although antiparietal cell antibodies are present in 90% of patients with pernicious anemia, they are less specific than anti-IF antibodies and are found in 10% of the general population.

Methylmalonic Acid (MMA): Should be used to confirm deficiency in patients with low-normal B12 levels, but normal MMA does not exclude B12 deficiency.

Homocysteine: May be elevated in B12 deficiency, but is less specific than MMA.

Clinical Assessment:

- Complete blood count with peripheral smear (macrocytic anemia, hypersegmented neutrophils)[11]
- Comprehensive symptom evaluation (neurological, psychiatric, gastrointestinal)[12]
- Family history of autoimmune conditions[13]
- Personal history of autoimmune disorders[14]

Diagnostic Principles

- Clinical symptoms should guide diagnosis rather than isolated laboratory values
- Normal laboratory values (including serum B12, holotranscobalamin, MMA, and homocysteine) do not exclude B12 deficiency
- Significant percentage of pernicious anemia patients have negative antibody tests
- When clinical suspicion is high, empirical treatment is appropriate and should not be delayed
- Treatment response to B12 therapy can confirm diagnosis when laboratory tests are inconclusive

Treatment Essentials

Evidence-Based Protocol:

- Neurological involvement: 1000 mcg IM or SC alternate days until no further improvement, then as required to maintain improvement[1,31,33]
- No neurological involvement: 1000 mcg IM or SC three times weekly for 2 weeks, then every 2-3 months[1,31,33]
- Lifelong treatment required
- Many patients require more frequent dosing than standard protocols[16,21,31]

Common Treatment Errors:

- Using serum B12 or other laboratory values to guide treatment frequency
- Inadequate initial loading doses
- Premature reduction of injection frequency
- Dismissing symptom recurrence between injections
- Supplementing folic acid without documented folate deficiency

---

This completes the ***Quick Reference for Physicians.***

A ***Comprehensive Clinical Guide*** follows.

Table of Contents

Pernicious Anemia Diagnosis and Management: Clinical Guide

Understanding the Severity of Pernicious Anemia

Pernicious anemia is a progressive neurological condition. Vitamin B12 deficiency can be responsible for neurological impairment, which can occur in the absence of any anemia or macrocytosis (approximately 25-30% of PA cases). Neuropsychiatric symptoms are often the first manifestation. Even though the name Pernicious Anemia suggests anemia is always present, this is often not the case.

Without adequate treatment, patients will develop:

- Permanent spinal cord damage (subacute combined degeneration)[4,5]
- Irreversible peripheral neuropathy[3]
- Permanent cognitive impairment and dementia[4]
- Psychiatric symptoms that are often misdiagnosed as primary mental illness[6]
- Progressive disability and loss of independence[7]

Early intervention is essential. Neuropsychiatric symptoms can precede hematological signs and are often the presenting manifestation of B12 deficiency[4]. Typically, neurological symptom improvement is slower than hematological improvement, and the degree of neurological recovery is inversely proportional to the severity and duration of symptoms before treatment[5]. Delayed or inadequate treatment guarantees permanent neurological damage[3].

Critical Point: Neurological signs usually generate a clinical picture of combined sclerosis of the spinal cord[1]. It should also be kept in mind that neurological manifestations may only partially regress despite prolonged and high-dose vitamin B12 therapy, leading to – at times – irreversible sequelae[6].

Treatment Protocol Errors to Avoid

Common Mistakes

1. Using laboratory values to guide treatment frequency

Since laboratory B12 concentrations do not always mirror the clinical picture, these markers are not optimally suited to monitor the effect of treatment. Use clinical symptoms to determine injection frequency[1,5].

Serum B12, holotranscobalamin, MMA, and homocysteine can all normalize before tissue repair occurs. In pernicious anemia and other malabsorption states, blood transport markers do not reliably reflect nervous system B12 status.

2. Inadequate loading doses

Standard "monthly B12 shots" are insufficient for initial treatment[16]. Guidelines from the British Society for Haematology recommend injections three times per week for two weeks in patients without neurologic deficits. If neurologic deficits are present, injections should be given every other day for up to three weeks or until no further improvement is noted[1].

3. Premature reduction of treatment frequency

Major Error: Reducing injection frequency as soon as patient feels better or laboratory values normalize[17].

Many patients require more frequent dosing than standard protocols suggest[17],[21],[31]. Once a diagnosis of B12 deficiency due to poor absorption of B12 has been made, therapy should be maintained lifelong.

4. Dismissing symptom recurrence between injections

This is one of the most common and consequential errors in pernicious anemia management. When patients report symptoms returning before their next scheduled injection, this represents clinical evidence of inadequate dosing frequency.

See the section "When Patients Report Symptoms Returning Between Injections" below for detailed guidance.

5. Inappropriate folic acid supplementation

Folate levels should be determined to exclude macrocytic anemia secondary to folate deficiency and because treating B12-deficient patients with folate alone may worsen associated neurologic damage. Only supplement folic acid if folate deficiency is documented[19].

Evidence-Based Treatment Protocol

Initial Phase:

- Treatment of pernicious anemia and other macrocytic anemias with neurological involvement: 1000 mcg on alternate days until no further improvement, then frequency adjusted to maintain improvement[1],[31],[33]
- Treatment of pernicious anemia and other macrocytic anemias without neurological involvement: 1000 mcg three times per week for 2 weeks, then frequency adjusted to maintain symptom control[1],[31],[33]

Maintenance Phase:

Standard maintenance protocols suggest B12 every 1-3 months, but this represents a starting point, not a fixed endpoint. Clinical reality shows significant individual variation:

- Many patients require more frequent dosing than standard protocols[21],[31]
- Frequency must be individualized based on symptom control, not laboratory values[20]
- No maximum injection frequency exists—some patients require weekly or twice-weekly injections for adequate symptom control
- Symptom recurrence before next scheduled injection indicates inadequate dosing frequency
- Adjustment should be based on clinical response over 6-12 months

The lack of clinical improvement after 4–8 weeks for anemia and after 6–12 months for neurological signs could suggest that the symptoms are not due to B12 deficiency or that the dose of vitamin B12 or the route of administration needs to be adjusted to the severity of symptoms.

Route of Administration:

Intramuscular or subcutaneous B12 is the standard route for pernicious anemia treatment, particularly when neurological symptoms are present.

Some studies have reported that oral B12 at very high doses (1000-2000 mcg daily) can normalize serum B12 and metabolic markers (MMA, homocysteine) in pernicious anemia patients through passive diffusion. However, these studies have significant limitations:

- Small sample sizes and short follow-up periods (typically under 18 months)
- Outcomes measured were blood markers (serum B12, MMA, homocysteine), not direct assessment of intracellular B12 levels, neurological function, or myelin integrity
- No long-term studies measuring neurological outcomes over years or decades
- Blood markers can normalize while cellular deficiency persists

Clinical Decision Making:

Given that:

- Neurological damage can become irreversible
- Laboratory markers don't reliably reflect cellular B12 status or myelin protection
- Treatment response must be individualized based on symptoms
- The consequences of under-treatment are permanent neurological damage

Intramuscular/subcutaneous administration remains the recommended route, particularly for:

- Patients with neurological involvement
- Initial treatment and loading phases
- Patients whose symptoms don't adequately respond to treatment

Treatment frequency should be determined by clinical response, not theoretical absorption calculations or blood test results.

When Patients Report Symptoms Returning Between Injections

This is one of the most common presentations in inadequately treated pernicious anemia and is frequently dismissed or discounted by healthcare providers who rely on laboratory values rather than clinical assessment.

Inadequate Treatment Indicators

Patients may report:

- Symptoms improve for days or weeks after injection, then gradually return
- Symptom-free interval becomes progressively shorter over time
- Clear pattern of symptom relief after injection followed by deterioration
- "Counting days" until next injection
- Functional decline in the week(s) before scheduled injection

Common returning symptoms include:

- Fatigue and exhaustion
- Cognitive difficulties (brain fog, memory problems, difficulty concentrating)
- Mood changes (anxiety, depression, irritability)
- Neurological symptoms (tingling, numbness, balance problems)
- Sleep disturbances

This pattern represents clinical evidence that:

- The current dosing interval is inadequate for this patient's needs
- Tissue B12 levels are dropping below the threshold needed for normal function
- The patient is experiencing repeated cycles of partial deficiency between injections
- Risk exists for progressive neurological damage if dosing remains inadequate

Healthcare providers may discount these reports because:

- Laboratory values (serum B12, MMA) drawn shortly after injection appear normal
- Belief that "monthly injections are standard" and should be sufficient
- Assumption that symptoms are psychological or unrelated to B12
- Lack of awareness that individual B12 utilization and storage capacity vary significantly
- Unfamiliarity with the disconnect between blood markers and tissue B12 status

Appropriate Clinical Response

When patients report symptom recurrence between injections:

1. Recognize this as valid clinical data

- The patient's symptom pattern is more reliable than laboratory values for guiding treatment frequency
- This is not "placebo effect" or "drug-seeking behavior"—it represents inadequate tissue B12 repletion

2. Adjust injection frequency

- Increase frequency until patient maintains symptom control throughout the dosing interval
- Common adjustments: monthly → every 3 weeks → every 2 weeks → weekly
- Some patients require twice-weekly injections for adequate control
- There is no maximum injection frequency

3. Monitor clinical response over time

- Allow 6-12 months to assess neurological response
- Adjust frequency based on sustained symptom control, not laboratory values
- Once stable dosing is established, it should be maintained lifelong

4. Do not reduce frequency based on laboratory normalization

- Normal serum B12, holotranscobalamin, or MMA after injection does not indicate adequate tissue stores throughout the dosing interval
- If symptoms recur, the interval is too long regardless of peak laboratory values

Key Principle

In pernicious anemia, the goal is not to normalize laboratory values but to prevent neurological damage and maintain optimal function. If standard dosing achieves normal labs but the patient experiences symptom recurrence, the dosing is inadequate.

The Critical Importance of Early Diagnosis and Aggressive Treatment

Early Diagnosis Matters:

- Neurological damage is the first effect of B12 deficiency[38]—neuropsychiatric symptoms are often the first manifestation
- Neurologic damage occurs independently of hematologic manifestations in pernicious anemia
- Early pernicious anemia symptoms are mild—so mild that some people simply learn to live with feeling tired, lightheaded or breathless. But diagnosing pernicious anemia early can prevent serious and irreversible problems with your nervous system[39]

Aggressive Treatment is Essential:

- If patients are not treated early in the disease, neurologic complications can become permanent
- Although B12 supplementation stops progression and improves neurologic deficits in most patients with subacute combined degeneration, evidence shows complete resolution only occurs in a small percentage of them
- Standard monthly injections are inadequate for many patients with neurological involvement

Red Flags: When to Suspect Pernicious Anemia

Neurological Symptoms (The Primary Treatment Indicator):

- Peripheral neuropathy (tingling, numbness, burning in hands/feet)[23]
- Subacute combined degeneration of the spinal cord[24]
- Balance problems, unsteady gait, falls[25]
- Cognitive impairment, memory problems, dementia-like symptoms[26]
- Psychiatric symptoms: depression, anxiety, mood swings, psychosis[27]
- Fatigue that doesn't respond to rest[28]

Critical Understanding: Severe neurologic impairment, usually subacute combined system degeneration, occurs in cobalamin deficiency. However, vitamin B12 deficiency can also present as peripheral neuropathy, psychosis, depression, or leukoencephalopathy.

Diagnostic Decision Making

When laboratory values are normal or borderline but clinical suspicion is high:

- Laboratory measurements may not reliably detect deficiency
- Do not dismiss symptoms based solely on laboratory values[46]
- Do not rule out pernicious anemia based on negative antibody tests—40-60% of pernicious anemia patients have negative intrinsic factor antibody results[1]
- Empirical treatment is appropriate when clinical suspicion is high
- Monitor clinical response: improvement with treatment confirms diagnosis even when laboratory tests were inconclusive

Monitoring Treatment:

- Recognition of clinical symptoms should receive the highest priority
- There is no need to monitor laboratory values in patients receiving regular parenteral vitamin B12 treatment[41]
- Adjust treatment frequency based on symptom control, not laboratory normalization
- If symptoms recur between injections, increase frequency

Differential Diagnosis

Pernicious anemia must be differentiated from other conditions that can present with similar hematological and neurological findings:

Primary Mimics (High Risk of Misdiagnosis)

- Myelodysplastic Syndrome (MDS) - Can have identical bone marrow appearance with dysplastic changes, blasts, and cytopenias. Always check B12/folate before bone marrow biopsy[42]
- Acute Leukemia - May present with pancytopenia and abnormal blood cells
- Folate Deficiency - Identical megaloblastic anemia; requires concurrent folate testing
- Iron Deficiency Anemia - Can coexist with PA (up to 50% of patients); may mask macrocytosis[43]

Other B12 Deficiency Causes

- Dietary Deficiency - Vegans, strict vegetarians
- Malabsorption Syndromes - Crohn's disease, celiac disease, bacterial overgrowth
- Surgical Causes - Gastrectomy, gastric bypass, ileal resection
- Medication-Induced - Proton pump inhibitors, metformin, H2 blockers
- Parasitic Infection - Diphyllobothrium latum (fish tapeworm)

Associated Conditions

- Hypothyroidism - Can coexist and cause similar fatigue/cognitive symptoms
- Autoimmune Disorders - May present concurrently (thyroid disease, diabetes)

Long-Term Monitoring and Surveillance

Gastric Cancer Surveillance[44]

Pernicious anemia patients have 2-3 fold increased risk of gastric cancer and 11-fold increased risk of gastric carcinoid tumors.

European Guidelines Recommendations:

- Initial endoscopy with topographical biopsies to confirm corpus-predominant atrophic gastritis
- Surveillance endoscopy every 3-5 years for patients with advanced atrophy
- More frequent monitoring for patients with pre-neoplastic lesions

Clinical Decision Making:

- First gastroscopic follow-up should be performed relatively soon after diagnosis

- Consider 3-year intervals for patients under 60 years
- 4-year intervals may be safe for routine surveillance in asymptomatic patients

Iron Deficiency Monitoring[42]

Up to 50% of pernicious anemia patients develop concurrent iron deficiency anemia.

- Monitor iron panel annually (ferritin, iron, TIBC)
- Iron deficiency may mask macrocytosis, complicating diagnosis
- Achlorhydria prevents adequate iron absorption from food

Associated Autoimmune Conditions[43]

Screen for related autoimmune disorders:

- Thyroid disease (40% prevalence) - TSH, anti-TPO antibodies
- Type 1 diabetes (10% prevalence) - glucose, HbA1c
- Addison's disease - morning cortisol if clinically indicated
- Vitiligo, myasthenia gravis - clinical examination

Treatment Response Monitoring

Hematologic Response:

- Reticulocytosis within 5-7 days of treatment initiation
- Hemoglobin increases ~1 g/dL per week after initial reticulocyte response
- Complete hematologic recovery typically within 6-8 weeks

Neurologic Response:

- Improvement typically slower than hematologic response
- Maximum neurologic recovery may take 6-12 months or longer
- Degree of recovery inversely related to duration/severity before treatment
- Monitor clinical function, not laboratory values

Contraindications and Drug Interactions

Medications Affecting B12 Absorption[46]

High-Risk Medications:

- Proton Pump Inhibitors - Long-term use (>12 months) significantly impairs B12 absorption
- Metformin - Blocks B12 absorption; monitor patients on long-term therapy
- H2 Receptor Blockers - Reduce gastric acid needed for B12 release from food

Management:

- Consider B12 supplementation for patients on long-term acid-suppressing therapy
- Monitor B12 levels annually in patients taking metformin >4 months

Critical Drug Interactions

Folic Acid Supplementation:

- Never give folic acid alone to suspected B12-deficient patients
- Folic acid can temporarily improve anemia while allowing neurological damage to progress
- Always ensure adequate B12 replacement before or concurrent with folate therapy

Treatment Route Considerations

Oral Therapy Contraindications:

- Active malabsorption syndromes
- Severe neurological involvement requiring rapid correction
- Poor compliance expected
- Concurrent use of medications significantly impairing absorption

Special Populations

Pregnancy and Reproductive Health[47]

Maternal Considerations:

- B12 deficiency can cause infertility (usually reversible with treatment)
- Pregnancy increases B12 requirements
- Untreated deficiency associated with neural tube defects[45]
- Routine folic acid supplementation can mask maternal B12 deficiency by correcting anemia while neurological risk persists

Management:

- Ensure adequate B12 status before conception
- Monitor B12 levels during pregnancy
- Continue treatment throughout pregnancy and lactation

Pediatric Considerations[55]

Juvenile Pernicious Anemia:

- Rare autosomal recessive condition
- Usually presents between 4-28 months
- Often associated with proteinuria and urinary tract malformations
- Requires lifelong treatment

Congenital Forms:

- Intrinsic factor deficiency
- Transcobalamin II deficiency
- Earlier presentation than adult-onset disease

Elderly Patients[48]

Special Considerations:

- Higher prevalence (1.9% in patients >60 years)
- Often presents with atypical symptoms
- Concurrent medications may complicate diagnosis
- Higher risk of delayed diagnosis due to non-specific symptoms
- Consider B12 deficiency in any elderly patient with cognitive decline

Prognosis and Expected Outcomes

Hematologic Prognosis

Excellent with proper treatment:

- Complete resolution of anemia typically within 6-8 weeks
- Normal red blood cell production restored
- Requires lifelong maintenance therapy

Neurologic Prognosis[49]

Variable, depending on duration before treatment:

- Early treatment - Complete or near-complete neurologic recovery possible
- Delayed treatment - Partial recovery; some deficits may be permanent
- Severe/prolonged deficiency - Irreversible neurological damage likely

Specific Outcomes:

- Peripheral neuropathy - Often improves significantly
- Cognitive symptoms - Usually reversible if treated early
- Subacute combined degeneration - May have residual deficits
- Psychiatric symptoms - Generally respond well to treatment

Long-term Complications[50]

With Adequate Treatment:

- Normal life expectancy
- Prevention of progressive neurological damage
- Reduced risk of severe anemia complications

Inadequate or Delayed Treatment:

- Progressive neurological deterioration
- Permanent cognitive impairment
- Increased mortality risk
- Higher cancer surveillance needs

Quality of Life

Most patients experience:

- Significant improvement in fatigue and cognitive function

- Stabilization or improvement of neurological symptoms
- Good long-term quality of life with proper treatment adherence

Key Takeaways for Clinical Practice

- Neurological damage is the first effect of B12 deficiency, occurring before or without anemia[31]
- No blood test reliably reflects nervous system/tissue status in malabsorption [30]
- Clinical symptoms guide diagnosis and treatment frequency[31]
- Normal laboratory values (including serum B12, holotranscobalamin, MMA, homocysteine) do not exclude B12 deficiency
- Pernicious anemia requires lifelong treatment[32]
- Many patients require more frequent injections than standard protocols suggest[31]
- Symptom recurrence between injections indicates inadequate dosing frequency
- Early diagnosis and treatment prevent irreversible neurological damage[34]
- Negative antibody tests do not rule out pernicious anemia—40-60% of patients test negative[1]
- Folic acid supplementation requires documented deficiency[35]
- When clinical suspicion is high and tests are normal or borderline, empirical treatment is appropriate
- When in doubt, treat—the risks of undertreatment far exceed those of overtreatment[36]

For Professional Use Only

References

1. British Committee for Standards in Haematology (BCSH). Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol. 2014;166(4):496–513.
2. Wolffenbuttel B H, Owen P J, Ward M, Green R. Vitamin B12 BMJ 2023; 383 :e071725 doi:10.1136/bmj-2022-071725.
3. Green R. Vitamin B12 deficiency from the perspective of a practicing hematologist. Blood. 2017;129(19):2603–2611.
4. Langan RC, Goodbred AJ. Vitamin B12 deficiency: recognition and management. Am Fam Physician. 2017;96(6):384–389.
5. Obeid R, Andrès E, Češka R, et al. Diagnosis, Treatment and Long-Term Management of Vitamin B12 Deficiency in Adults: A Delphi Expert Consensus. *J Clin Med*. 2024;13(8):2176. Published 2024 Apr 10. doi:10.3390/jcm13082176.
6. Andres E, Serraj K, Zhu J, Noel E. Optimal management of pernicious anemia. J Blood Med. 2012;3:97–103.
7. Seage CH, Bennett A, Ward N, et al. A Systematic Review of Symptoms of Pernicious Anemia. Food and Nutrition Bulletin. 2024;45(1_suppl). doi:10.1177/03795721241227016.
8. Solomon LR. Cobalamin-responsive disorders in the ambulatory care setting: unreliability of cobalamin, methylmalonic acid, and homocysteine testing. Blood. 2005;105(3):978–985.
9. Nexo E, Hoffmann-Lücke E. Holotranscobalamin, a marker of vitamin B-12 status: analytical aspects and clinical utility. Am J Clin Nutr. 2011;94(1):359S–365S.
10. Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31–62.
11. Savage DG, Lindenbaum J, Stabler SP, Allen RH. Sensitivity of serum methylmalonic acid and total homocysteine for diagnosing cobalamin and folate deficiencies. Am J Med. 1994;96(3):239–246.
12. Oh R, Brown DL. Vitamin B12 deficiency. Am Fam Physician. 2003;67(5):979–986.
13. Shipton MJ, Thachil J. Vitamin B12 deficiency—a 21st-century perspective. Clin Med (Lond). 2015;15(2):145–150.
14. Toh BH, van Driel IR, Gleicher GJ. Pernicious anemia. N Engl J Med. 1997;337(20):1441–1448.
15. van Asselt DZB, et al. Cobalamin supplementation improves cognitive function in elderly cobalamin-deficient patients. J Gerontol A Biol Sci Med Sci. 2001;56(12):M775–M779.
16. Healton EB, Savage DG, Brust JC, Garrett TJ, Lindenbaum J. Neurologic aspects of cobalamin deficiency. Medicine (Baltimore). 1991;70(4):229–245.
17. Kwong JC, et al. Effects of proton pump inhibitors on vitamin B12 absorption. Drug Saf. 2008;31(9):769–774.
18. Freeman AG. Cyanocobalamin—a case for withdrawal: discussion paper. J R Soc Med. 1992;85(11):686–687.
19. Reynolds E. Vitamin B12, folic acid, and the nervous system. Lancet Neurol. 2006;5(11):949–960.
20. Kuzminski AM, Del Giacco EJ, Freeman AG. Effective treatment of cobalamin deficiency with oral cobalamin. Blood. 1998;92(4):1191–1198.
21. Butler CC, Vidal-Alaball J, Cannings-John R, Goringe A, McCaddon A. Oral versus intramuscular vitamin B12 for vitamin B12 deficiency: a systematic review. BMJ. 2006;332(7531):385–389.
22. Dali-Youcef N, Andres E. An update on cobalamin deficiency in adults. QJM. 2009;102(1):17–28.

23. Hemmer B, Glocker FX, Schumacher M, Deuschl G, Lücking CH. Subacute combined degeneration: clinical, electrophysiological, and imaging findings. J Neurol Neurosurg Psychiatry. 1998;65(6):822–827.
24. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med. 1988;318(26):1720–1728.
25. Goebels N, Soyka M. Dementia associated with vitamin B12 deficiency: case reports and literature review. J Neuropsychiatry Clin Neurosci. 2000;12(3):389–394.
26. Hutto BR. Folate and cobalamin in psychiatric illness. Compr Psychiatry. 1997;38(6):305–314.
27. Wolffenbuttel, B. H. R., Wouters, H. J. C. M., Heiner-Fokkema, M. R., & van der Klauw, M. M. (2019). The Many Faces of Cobalamin (Vitamin B12) Deficiency. Mayo Clinic proceedings. Innovations, quality & outcomes, 3(2), 200–214. https://doi.org/10.1016/j.mayocpiqo.2019.03.002.
28. Andres E, Vogel T, Federici L, et al. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ. 2004;171(3):251–259.
29. Kumar N. Neurologic aspects of cobalamin (B12) deficiency. Handb Clin Neurol. 2014;120:915–926.
30. Devalia V, Hamilton MS, Molloy AM. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol. 2014;166(4):496–513.
31. Pernicious Anaemia Society. Clinical Guidelines and Resources. 2024. Available from: https://pernicious-anaemia-society.org/
32. National Institute for Health and Care Excellence (NICE). Vitamin B12 deficiency in over 16s: diagnosis and management. NICE Guideline NG239. March 2024.
33. BC Guidelines. Cobalamin (Vitamin B12) and Folate Deficiency – Diagnosis and Management. Government of British Columbia; 2015.
34. Solomon LR. Disorders of cobalamin metabolism: emerging concepts. Am J Hematol. 2007;83(4):341–345.
35. NHS. Vitamin B12 or folate deficiency anaemia – Treatment. NHS; 2023. Available at: https://www.nhs.uk/conditions/vitamin-b12-or-folate-deficiency-anaemia/treatment/
36. Green R, Allen LH, Bjørke-Monsen AL, et al. Vitamin B12 deficiency. Nat Rev Dis Primers. 2017;3:17040.
37. Watanabe F. Vitamin B12 sources and bioavailability. Exp Biol Med (Maywood). 2007;232(10):1266–1274.
38. Cleveland Clinic. Pernicious Anemia. Cleveland Clinic; 2023. https://my.clevelandclinic.org
39. Carmel R, Johnson CS. Racial patterns in pernicious anemia: early onset and antibody rates in Blacks. N Engl J Med. 1978;298(12):647–651.
40. Andres E, Affenberger S, Vinzio S, et al. Optimal management of pernicious anemia. J Blood Med. 2012;3:97–103.
41. Dinis-Ribeiro M, et al. ESGE MAPS II guidelines: Management of precancerous gastric conditions. Endoscopy. 2019;51(4):365–388.
42. Lam JR, Schneider JL, Quesenberry CP, Corley DA. Concurrent iron and vitamin B12 deficiency: prevalence and diagnostic challenges. J Clin Pathol. 2017;70(10):822–826.
43. Betterle C, et al. Autoimmune polyendocrine syndromes: rare diseases with complex clinical features. J Clin Endocrinol Metab. 2004;89(4):1525–1534.
44. Long AN, Atwell SE, Yoo W, Solomon D. Proton pump inhibitors, metformin, and B12 deficiency. Curr Opin Endocrinol Diabetes Obes. 2017;24(2):150–156.

45. Nie L, Liu X, Li X, Ren Z, Cheng X, Wu Y, Li Z, Liu J. Beyond Folate: The Emerging Role of Maternal Vitamin B12 in Neural Tube Development. *Nutrients*. 2025; 17(12):2040. https://doi.org/10.3390/nu17122040.
46. O'Leary F, Samman S. Vitamin B12 in health and disease. Nutrients. 2010;2(3):299–316.
47. Healton EB, Savage DG, Brust JC, Lindenbaum J. Neurologic aspects of cobalamin deficiency: recovery potential and prognosis. Medicine (Baltimore). 1991;70(4):229–245.
48. O'Leary F, Samman S. Vitamin B12 and quality of life outcomes. Nutr Rev. 2011;69(6):349–359.
49. Stabler SP. Clinical practice: Vitamin B12 deficiency. N Engl J Med. 2013;368(2):149–160.
50. Carmel R. Disorders of cobalamin metabolism: clinical concepts. Am J Hematol. 2007;83(4):341–345.
51. Lee MS, et al. Neurologic recovery after vitamin B12 therapy in older adults. J Am Geriatr Soc. 2000;48(10):1275–1278.
52. Andrès E. Vitamin B12 (cyanocobalamin/hydroxocobalamin) therapy: a reappraisal. Hematology. 2022;27(1):13–22.
53. Carmel R. Cobalamin, the stomach, and aging. Am J Clin Nutr. 1997;66(4):750–759.
54. van Walraven C, Naylor CD. Vitamin B12, physician awareness, and patient outcomes: a cohort study. J Am Geriatr Soc. 1999;47(8):935–942.
55. Kuzminski AM, et al. Oral vitamin B12 replacement effectiveness and factors influencing it. Blood. 1998;92(4):1191–1198.
56. Andres E, Federici L, Vogel T, et al. Autoimmune gastritis and pernicious anemia: clinical presentation and epidemiology. J Blood Med. 2015;6:59–64.
57. Tardy C, et al. Long-term follow-up of patients with pernicious anemia treated with oral vitamin B12. Hematology. 2019;24(1):139–146.
58. Silva M, et al. Impact of vitamin B12 deficiency diagnosis delay on neurological outcomes. Neurol Sci. 2021;42(1):201–207.
59. O'Leary F, Samman S. Updated insights on vitamin B12 intake and neurological function. Nutrients. 2020;12(3):786.
60. Green R, Allen LH, Bjørke-Monsen AL, et al. Advances in diagnosis and treatment of vitamin B12 deficiency. Nat Rev Dis Primers. 2022;8(1):54.

Available online at: https://dittany.com/preventing-neurological-damage/